Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 | P23458 | 4/20 | 0.47 |
| ▸ | JAK2 | O60674 | 3/20 | 0.47 |
| ▸ | BRD4 | O60885 | 6/20 | 0.47 |
| ▸ | JAK3 | P52333 | 4/20 | 0.46 |
| ▸ | CACNA2D1 | P54289 | 5/20 | 0.44 |
| ▸ | SYK | P43405 | 1/20 | 0.44 |
| ▸ | INSR | P06213 | 1/20 | 0.44 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.44 |
| ▸ | EGFR | P00533 | 2/20 | 0.42 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL270267 | 0.88 | BRD4 (0.51) | JAK1JAK2BRD4JAK3SYK | |
| SCHEMBL12109566 | 0.84 | JAK1 (0.59) | JAK1JAK2BRD4JAK3EGFR | |
| SCHEMBL264968 | 0.84 | BRD4 (0.64) | JAK1JAK2BRD4JAK3 | |
| SCHEMBL310838 | 0.82 | CACNA2D1 (0.49) | JAK1JAK2BRD4JAK3CACNA2D1 | |
| SCHEMBL14536300 | 0.82 | PDGFRB (0.56) | JAK1JAK2BRD4JAK3 | |
| SCHEMBL14390070 | 0.79 | BRD4 (0.46) | JAK1JAK2BRD4JAK3CACNA2D1 | |
| SCHEMBL305045 | 0.74 | SYK (0.78) | JAK3SYKEGFR | |
| SCHEMBL305864 | 0.72 | JAK1 (0.59) | JAK1JAK2BRD4JAK3SYK | |
| SCHEMBL12321383 | 0.72 | SYK (0.55) | JAK1JAK2JAK3SYKEGFR | |
| SCHEMBL301773 | 0.71 | MAP3K7 (0.60) | JAK3SYKEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1951684-B1 | BI-ARYL META-PYRIMIDINE INHIBITORS OF KINASES | TARGEGEN INC (US) | 2016-07-13 | — | — | EP | disclosed |
| US-8133900-B2 | Use of bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2012-03-13 | — | — | US | disclosed |
| US-20110212077-A1 | BI-ARYL META-PYRIMIDINE INHIBITORS OF KINASES | TARGEGEN, INC. (US) | 2011-09-01 | — | — | US | disclosed |
| US-20090286789-A1 | Bi-Aryl Meta-Pyrimidine Inhibitors of Kinases | TARGEGEN, INC. (US) | 2009-11-19 | — | — | US | disclosed |
| US-7528143-B2 | Bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2009-05-05 | — | — | US | disclosed |
| US-20070191405-A1 | Bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2007-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286789-A1 | Bi-Aryl Meta-Pyrimidine Inhibitors of Kinases | JAK2, TYK2, LTK | JAK1 6/4885JAK2 1/4885BRD4 156/4885 |
| US-20070191405-A1 | Bi-aryl meta-pyrimidine inhibitors of kinases | JAK2, TYK2, JAK3 | JAK1 4/4885JAK2 1/4885BRD4 142/4885 |
| US-20110212077-A1 | BI-ARYL META-PYRIMIDINE INHIBITORS OF KINASES | JAK2, TYK2, JAK3 | JAK1 4/4885JAK2 1/4885BRD4 142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.